On June 14, 2013, FDA conducted a public meeting on human immunodeficiency virus (HIV) Patient-Focused Drug Development and HIV Cure Research. FDA is interested in obtaining patient input on the impact of HIV on daily life, currently available therapies to treat the condition, and patients’ views on issues related to HIV cure research.
|June 14, 2013|
|9:30 a.m. to 5:30 p.m|
FDA White Oak Campus 10903 New Hampshire Ave.
To register for this meeting, visit http://patientfocusedhiv.eventbrite.com.
To submit comments to the docket, go to http://www.regulations.gov/#!docketDetail;D=FDA-2013-N-0473.
The comment period has re-opened. Electronic and written comments may be submitted to the docket until September 3, 2013.
- Part 1 - Opening to Morning Break: https://collaboration.fda.gov/p936e3j52j3/
Part 2 - Morning Break to Lunch: https://collaboration.fda.gov/p2g9irtlj7q/
Part 3 - Lunch to Afternoon Break: https://collaboration.fda.gov/p8ozycpowb2/
Part 4 - Afternoon Break to Closing: https://collaboration.fda.gov/p60xqo6slgh/
- The Voice of the Patient Report: HIV (PDF - 350KB)
HIV Patient-Focused Drug Development and HIV Cure Research: Reopening of Comment Period
Federal Register Notice (8/2/2013)
- HIV Patient-Focused Drug Development and HIV Cure Research: Public Meeting
Federal Register Notice (5/21/2013)
- Meeting Agenda (PDF - 151KB)
- Meeting Slides (PDF - 545KB)
- Meeting Transcript (PDF - 12.4MB)
Background Document: HIV Patient-Focused Drug Development and HIV Cure Research(PDF - 114KB) Webinar: Background on FDA and Patient-Focused Drug Development[ARCHIVED]